Canada-based CRO Biopharma Services passes WHO inspection

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/IvinRadkov)
(Image: Getty/IvinRadkov)

Related tags: WHO, CRO, assessment, compliance, Inspection, Fda, Ema, bioequivalence, Research, Clinical trial

WHO recently assessed Biopharma Services, which demonstrated compliance across multiple regulatory and organizational guidelines – opening the doors to conduct more work with the WHO foundations.

Following the assessment, Biopharma Services, a Phase I/IIa and bioequivalence contract research organization (CRO), received a status of compliance from the World Health Organization (WHO) valid through January 1, 2021.

This status was received after the assessment by WHO demonstrated that Biopharma’s site met the guidelines of current good laboratory practices (cGLP), good clinical practice (GCP), as well as the European Medicines Agency regulations (EMA), Medicines and Healthcare Regulatory Association (MHR) guidelines, and International Standardization Organization (ISO) processes.

The assessment included the review of two clinical studies found to be in compliance with regulatory guidelines required by the World Health Organization’s (WHOs) for in vivo ​bioequvialance studies. The studies were conducted at the company’s Toronto, Canada site.

Renzo DiCarlo, CEO of Biopharma Services told us that the status of compliance “will also open the door for us [the company] to work with many WHO foundations.”

According to Biopharma, the assessment is one of first steps in the prequalification process when submitting a finished pharmaceutical product as an expression of interest for product evaluation (EOI). EOIs are issued by WHO following the consultation of the organization’s disease programs and clinical specialists.

Previous to this assessment, the Canada-based company completed three FDA inspections​ in 2017 with zero observations. The company previously stated that it received no Form 483’s or observations after its FDA inspection in 2015 either.

The company has an additional site in Columbia, Missouri as well as affiliate relationships with Brazil, China, and the eastern European region. 

Related news

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more